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Abstract: Nuclear DNA binding and inhibition of growth of HeLa cells in culture were
determined after 24 h incubation with the ruthenium anticancer agents cis-[CI:z(NH3)4Ru]C1
(CCR) and (ImH)trans-[(Im):zClnRu] (ICR) as a function of [Ru], PO2, and added transferrin.
Consistent with the "activation-by-reduction" hypothesis, cytotoxicity andDNA binding for
both complexes increased under reduced oxygen conditions. Consistent with the "transfer-
rin-transport" hypothesis, inhibition of cell growth also increased with added transferrin for
both complexes. Despite their differences in charge, reduction potentials and substitution
rates, both complexes behaved remarkably similarly indicating a common mechanism of
action for both. Under atmospheric conditions (P02 = 159 torr), CCR inhibited HeLa cell
growth with IC50 = 3.5 tM, while that for ICR was 2.0 tM. The binding ofboth complexes
to DNA (RUDNA/PDNA) correlated with toxicity and was approximately linear in the concen-
tration of the ruthenium complex in the culture medium, [Ru]. For both complexes, IC50
values decrease and DNA binding increases with decreasing log(Po2). In general, DNA
binding at all oxygen pressures for both complexes is in the range of one Ru per 1000-2000
DNA base pairs at [Ru] = IC50.
Introduction
A number of ammine, amine and heterocyclic complexes ofruthenium exhibit: inhibi-
tion of DNA replication,’a mutagenic activity, induction of the SOS repair mechanism,3
binding to nuclear DNA,4 and reduction of RNA synthesis,5 so that DNA is strongly indi-
cated as the target molecule for ruthenium anticancer complexes.
While even some monoacido complexes such as [CH3CH2COO(NH3)RuIII]C104
exhibit good activity, generally multichloro compounds such as cis-[CI:(NH3)4Ru]CI,fac-
[C13(NH3)3Ru],,6 and Na trans-[(Im)2C14Ru]7 exhibit the best activity. In the case of the
latter compound, Keppler improved upon the activity of the poorly-soluble [C13(NH3)3Ru]
by charging with fewer nitrogen ligands and more halides to yield a more soluble anionic
complex.8-
An early working hypothesis regarding the design of Ru-anticancer agents suggested a
tumor selectivity based upon preferential reduction of RulII-prodrugs in the more reducing
environment of tumors.,a The RuII oxidation state should also be more prevalent inside of
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tumors, because in the hypoxic milieu of tumors there is less oxygen to oxidize RuII back to
the RuIII state. 13’14 Such "activation by reduction" in the tumor would favor intracellular
binding by the more rapidly substituting RuII ion. Since unprotonated imines are a preferred
binding site for RuII, the concentration of such sites in the N7 of purines in nucleic acids
suggests DNA as a preferred target.
Srivastava showed that some ruthenium complexes, such as RuC13, were transported
to the tumor by transferdn.5 Clarke suggested that multiacido ruthenium(III)complexes,
particularly anionic or neutral complexes with lower ligand field stabilization energies
and more rapid substitution rates, might also be transported in the blood by transferrin. 16-
19 Keppler and coworkers have since demonstrated that Natrans-[(Im)2C14Ru] and re-
lated complexes are indeed bound by apotransferrin in a reversible fashion such that the
trans-[(Im)Ru]3+ core remains intact. 18’19 It has been suggested that transferrin binding
by this type of complex follows the hydrolytic loss of a chloride ligand and may be spe-
cifically mediated by the protein.21 This result suggests that apotransferrin can act as a
natural and somewhat selective carder ofRuILdrugs into tumor cells owing to the large
number of transferrin receptors on the their surface. 19
While it has been implied that ruthenium complexes may operate either by the transfer-
rin-transport or activation-by-reduction mechanisms, these two mechanisms are not mutu-
ally exclusive. In this study, we correlate cytotoxicity and DNA binding in human cervical
cancer cells (HeLa) with oxygen tension and added apotransferrin concentration. Two active
antitumor ruthenium(III) compounds were chosen for investigation. The first, cis-
[C12(NH3)4Ru]C1 (CCR), yields the cationic species, cis-[C12(NH3)4Ru]+, in solution and
was considered more likely to function by the activation-by-reduction route, while the sec-
ond, [ImH]trans-[(Im)2C14Ru] (ICR), yields the anionic species, trans-[(Im)2C14Ru]-, whose
mechanism of action appeared to be transferrin-mediated. 18’9’21
Materials and Methods
Materials. cis-[Ru(Clz(NH3)4]C1 and trans-(ImH)[Ru(Im)2C14] (ImH = imidazolium
20,22 ion) were prepared by literature methods. Human serum apotransferrin was obtained
from Sigma Biochemical. Specialty gases (10% _+0.4 % Oz, 5% + 0.4%, CO2 balance N2 and
5%_+0.4% 02, 5%+0.4% CO2 balanceN by GC analysis) were obtained fromWesco. Buffer
A consists of: 66 I.tL of 4.5 M MgClz, 1.24 g of Tris-HC1 buffer, and 150 ktL of 2-
mercaptoethanol, diluted to one liter and adjusted to pH 7.4.
Cell Culture. The HeLa cell culture was a gift from the laboratory ofA.T. Annunziato
(Dept. Biology, Boston College). Cells were maintained in standard media: SMEM (Bio-
Whittaker), supplemented with 1% v/v 1-glutamine, 0.5% v/v penicillin-streptomycin, 10%
v/v fetal bovine serum, and 25 l.tM Hepes buffer in an incubator at 37 C, with stirring. The
culture was maintained at a concentration of 3 x 105 cells/mL as determined by counting on
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a counting slide. Millipore purified water was used in all dilutions and purifications involv-
ing cells and cellular materials.
Control and experimental cultures were begun at the concentration of 3 x 105 cells/mL
with a predetermined volume ofruthenium drug stock solution added through a sterile-filtering
(0.45 ktm) syringe to give the desired [Ru] in the final cell volume (50 mL). After 24 h, the
cultures were counted and the cell counts expressed as per cent growth relative to the control
(%Gr = 100 x NRu/Ncontrol), where Ncontrol is the cell density in the control and NRu is the cell
density in the Ru-added culture, or per cent inhibition (%IGr = 100 %Gr ). Controls (no Ru
added) involved a stock culture begun at 3 x 105 cells/mL and incubated for 24 h under the
same conditions as the Ru-added cultures. Controls and Ru-added cultures were run for each
type of experiment in which the partial pressure of oxygen and concentration of transferrin
were varied. Cultures were acclimated to the reduced oxygen conditions for 24 h prior to use
with the ruthenium complexes.
Ru-DNA Measurements. In order to extract the nuclear DNA, cultures were spun
down at approximately 1000 rpm for 10 minutes in an International Equipment Company
HN-S II centrifuge. The supernatant media was decanted from the cell pellet and the cell
pellet was resuspended and washed three times with bufferA to assure complete removal of
the Ru-containing media. The cell pellet was resuspended with buffer A, and lysed with a
glass homogenizer. A pellet of cell nuclei was isolated by centrifugation at approximately
2500 rpm (10 min.) and was resuspended, centrifuged and washed three times with buffer A.
Nuclei kept for further use were maintained in an ice bath or frozen overnight (-20 C) in
buffer A.
Nuclear membranes were lysed by a protease K solution (50M of 10% SDS, 20 ktM
10% protease K solution (Sigma) and 935 ktM of isolated nuclei). This solution was placed
in 1.5 mL Eppendorf tubes and left to digest for 24 h at 37 C. The DNA was isolated by
extraction with an equivalent volume of 1:1 phenol:chloroform. Phenol:chloroform. extrac-
tions were continued until there was no white, stringy material visible at the phase interface.
The solution was then extracted with an equivalent volume of molecular biology grade chlo-
roform, until there were no white filaments visible at the phase interface. The aqueous phase
was removed, and the DNA precipitated by the addition of 0.2 M sodium chloride in 70 %
ethanol. This solution was placed in a -78 C ice bath, and centrifuged in a Fisher microfuge
for 15 minutes. TheDNA pellet was retrieved by decanting off the ethanol, and resuspending
in another 1 mL of NaC1/ethanol solution. This DNA precipitation process was repeated
twice more to be sure no free Ru was carried through with the DNA. The DNA was quanti-
fied by UV absorption at 260 nm (e 6600 M- 1 cm- 1 per phosphate) in a Tris-EDTA buffer
at pH 7.8. Ruthenium was quantified by graphite-furnace atomic absorption (Perkin Elmer)
using the temperature program [time (s) andT (C)]: 4, 70; 5,200; 4, 800; 4, 1500; 1, 2800; 2,
2800. Results are reported as normalized perDNA nucleotide, i.e. as the ratio ofRu bound
to the DNA per DNA phosphate, RUDNA/PDNA.
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Results
In order to determine whether the ruthenium in the nuclear DNA samples was tightly
bound, several samples ofDNA extracted from HeLa cells that had been incubated with ICR
and CCR were subjected to exhaustive dialysis (3 x in 0.010M HEPES/0.010M NaHCO3)
and requantified. The relative changes in RUDNA/PDNA for each drug following dialysis
were not consistently lower than the original mean, but were randomly distributed with relative
standard deviations of+ 11% forCCR and + 8% for ICR, which is consistent with both drugs
binding tightly to the nuclear DNA.
The effect of hypoxia on cell toxicity and DNA binding was studied by running cul-
tures at one half and one quarter the partial pressure of oxygen present in the atmosphere.
Toxicity and nuclear DNA binding of CCR and ICR in HeLa cell cultures at the various
partial pressures of oxygen (Po2) are presented in Tables I and II and Figures 1 6. For
purposes of comparison, approximately linear ranges of the variables were treated by stan-
dard linear least squares methods. For all Po2’s, %IGr versus log[Ru] plots for both the CCR
the ICR complexes show a straightforward dose-response correlation (see Figs. 1, 3 and.5).
The corresponding IC50’s listed in Table I indicate increased toxicity of the ruthenium agents
as Poe decreases. Nuclear DNA binding by ruthenium, which is expressed as ruthenium
atoms per 1000 DNA nucleotides (see RUDNA/103PDA values in Table I), increased linearly
with [Ru] (see Figures 2, 4 and 6) and correlated with cell toxicity at any given Poe. When
expressed at a constant ruthenium concentration (10 gM), DNA binding increases with de-
creasing Poe; whereas at [Ru] ICs0, Ru-DNA binding remains relatively constant over the
varying oxygen pressures (Table I).
The effect of transferrin on cell toxicity and DNA binding of the ruthenium complexes
was studied by running cultures with added apotransferrin ([Tf]a) under normal atmospheric
conditions. Transferrin in the media itself is -3.3 gM. As added apotransferrin enhances cell
growth at low concentrations, but inhibits cell growth at [Tf]a > 0.7 gM (50 gg/mL), the
effect of apotransferrin was studied over the range 0 0.7 gM (see Figure 8). At constant
[Ru] = 10 gM, increasing [Tf]a resulted in increasing inhibition of cell growth for both
compounds. At the ICs0 values for [Tf]a under these conditions, ruthenium binding to DNA
was approximately twice that when no added transferrin was present (cf. RUDNA/103PDNA
values in Tables I and II).
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Table I. Concentrations ofruthenium complexes sufficient to inhibit cell growth to 50% of
that of the control (IC50), the amount ofRu bound toDNA per thousand nucleotides at [Ru]
= IC50, and the amount ofRu bound to DNA per thousand nucleotides at constant [Ru] (10
M) at PO2 = 159, 76, and 38 torr. ICR- [ImH]trans-[(Im)2C14Ru]. CCR- cis-
[C12(NH3)4Ru]C1.
Compound P02 IC50 (RUDNA/PDNA) X 103 (RUDNA/PDNA) X 103
(torr) (M) at [Ru] = ICs0 at [Ru] = lO
ICR 159 2.0 + 0.3 0.20 + 0.04 0.36 + 0.07
CCR 159 3.5 + 0.4 0.10 + 0.02 0.27 + 0.06
ICR 76 1.0 + 0.1 0.63 + 0.26 1.4 + 0.6
CCR 76 1.7 + 0.5 0.44 + 0.06 1.1 + 0.2
ICR 38 0.006 + 0.003 0.48 + 0.16 4.0 + 1.3
CCR 38 0.023 + 0.007 0.37 + 0.08 1.7 + 0.4
Table II. Concentrations of added apotransferrin ([Tf]a) sufficient to inhibit cell growth to
50% of that of the control (IC50) at [Ru] 10 tM and Poe 159 torr.
Compound ICso (tM) (RUDNA/PDNA) X 103
at [Ru] = 10 IM, [Tf]a = IC5o,
ICR 0.14 + 0.03 0.6 + 0.2
CCR 0.25 + 0.05 0.7 + 0.4
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Figure 1. Inhibition of HeLa cell growth versus [Ru] (l.tM) (logarithmic scale) for ruthe-
nium complexes at PO2 159 torr. Lines are logarithmic linear least squares fits. Circle
points, solid line, cis-[C12(NH3)4Ru]C1 (CCR); square points, dashed line,
[ImH]trans-[(Im)zC14Ru] (ICR).
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Figure 2. Binding of Ru to nuclear DNA versus culture [Ru] (gM) for ruthenium com-
plexes at PO2 = 159 torr. Lines are linear least squares fits. Circle points, solid line, cis-
[C12(NH)4Ru]C1 (CCR); square points, dashed line, [ImH]trans-[(Im)2C14Ru] (ICR).
3.0
2.5
2.0
1o5
1.0
0.5
0.0
[]
25 5O
[Ru] (pi)
75 100
202D. Frasca, J. Ciampa, J. Emerson, et al. Metal-BasedDrugs
Figure 3. Inhibition ofHeLa cell growth versus log[Ru] (gM) for ruthenium complexes at
PO2 76 torr. Lines are logarithmic linear least squares fits. Circle points, solid line, cis-
[C12(NH3)4Ru]C1 (CCR); square points, dashed line, [ImH]trans-[(Im)C14Ru] (ICR).
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Figure 4. Binding of Ru to nuclear DNA versus culture [Ru] (gM) for ruthenium com-
plexes at PO2 = 76 torr. Lines are linear least squares fits. Circle points, solid line, cis-
[C12(NH3)4Ru]C1 (CCR); square points, dashed line, [ImH]trans-[(Im)2C14Ru] (ICR).
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Figure 5. Inhibition of HeLa cell growth versus log[Ru] (ktM) for ruthenium complexes
at Po2 38 torr. Lines are logarithmic linear least squares fits. Circle points, solid line,
cis-[C12(NH3)4Ru]C1 (CCR); square points, dashed line, [ImH]trans-[(Im)2C14Ru] (ICR).
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Figure 6. Binding of Ru to nuclear DNA versus culture [Ru] (ktM) for ruthenium com-
plexes at P02 = 38 torr. Lines are linear least squares fits. Circle points, solid line, cis-
[C12(NH3)4Ru]C1 (CCR); square points, dashed line, [ImH]trans-[(Im)2C14Ru] (ICR).
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Figure 7. Correlation between toxicity (ICso values) and log[P02]. Lines are linear least
squares fits. Circle points, solid line, cis-[CI2(NH3)4Ru]C1 (CCR); square points, dashed
line, [ImH]trans-[(Im)C14Ru] (ICR).
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Figure 8. Inhibition of HeLa cell growth versus added transferrin, [Tf]a (gM), for cultures
with [Ru] = 10 ].tM ofCCR or ICR at PO2 = 159 torr compared to the relative growth with no
Ru present. The growth scale (%Gr) for the diamond points (top alternately dashed line,
no Ru present is relative to a control at [Ru] = 0. This line is fit by a 2-point running
average. Circle points, solid line, cis-[C12(NH3)4Ru]C1 (CCR); square points, dashed line,
[ImH]trans-[(Im)2C14Ru] (ICR) are for added [Tf]a at [Ru] = 10M ofCCR or ICR relative
to the control for the respective complex at the same [Ru]. These lines were fitted by a least
squares fit to a decreasing exponential equation. Growth in the [Ru] = 10tM controls relative
to [CCR] = 0 or [ICR] = 0 can be estimated from Figure 1.
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Discussion
Despite their differences in charge, the two complexes behaved remarkably alike through-
out this study. Both complexes appear to access nuclear DNA quite well at therapeutically
reasonable concentrations and the cytotoxicity of both is enhanced by added transferrin and
reduced oxygen. ICR is somewhat more toxic than CCR under all conditions. Plots of IC50
versus log[Po2] and RUDNA/103PDNA at [Ru] = 10gM versus log[Po2] (Figure 7, see Table I)
are linear indicating increased toxicity through increased DNA binding at lower oxygen
tensions for both complexes. While the effect of transferrin is higher for ICR, both drugs
exhibit significantly increased toxicity relative to the controls as the apotransferrin
concentration increases (Figure 8). As the data were treated by linear methods, the positive
intercepts on many of theDNA binding curves (Figs. 2, 4 and 6) are artifacts of the statistical
treatment, but are also consistent with an active transport mechanism providing entry for
these complexes into the HeLa cells.
As both complexes are firmly attached to the nuclear DNA, covalent binding appears
to be involved. Coordination by most mthenium(II) and ruthenium(III) complexes occurs at
the N7 of purine bases (usually guanine),3 but binding to the exocyclic amines of adenine
and cytosine is also possible,24 as is coordination across the double bond in uracils.25 Since
both ICR and CCR have at least two substitutable sites, DNA cross linking may be possible.
Consistent with the hypothesis that the antitumor activity of these complexes is depen-
dent upon DNA binding, the level of cytotoxicity (%IGr) and DNA binding (RuobaA/PoA)
correlate linearly (See Figures 1-6). The RUDNA/PDNA values at the IC50 concentrations of
the complexes remain relatively constant at all partial pressures of oxygen, indicating that
similar levels ofDNA binding are similarly toxic at all oxygen tensions (Table I). In harmony
with the activation-by-reduction hypothesis for both complexes, both the inhibition of cell
growth and DNA binding increase at constant [Ru] as PO2 decreases. In particular, at the
lowest Po2 (38 torr), the cytotoxicity of both complexes is greatly enhanced (Table I).
While the reduction potential at neutral pH (E’ -262 mV)26,27 of ICR is within a
biologically accessible range, significant reduction is not expected. However, reduction of
ICR is pH dependent and becomes more favored at lower pH.8 At pH 5, which results when
protons are pumped into the endosomes to release FeIII (and presumably RuIII) from the Fe-
transferrin-receptor complex,9’29 the reduction potential for ICR is ---100 mV. Reduction
should also be facilitated by loss of chloride (tl/2 3.5 h at 37 C),28 which should be substan-
tial over the 24 h experiments presented here. Since dissociation of C1- precedes or is con-
comitant with transferrin uptake,2 reduction of some metabolic forms of ICR would appear
likely.
As Sadler has pointed out, the anomalous pH behavior in the electrochemistry ofICR28
is reminiscent of that seen in the electrochemistry of [L(NH3)5OsIII,II] (L = imidazole ring
ligand),3 in which the d-orbitals are also expanded, but owing to a higher atomic number
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rather than anionic charge. It may be that imidazoles by virtue of their ability to serve as
rt---dr-donors or dn---rt-acceptors (depending on the energy and extension of the d-orbit-
als)27 help to provide a polarizable site for proton addition, which raises the reduction poten-
tial of the metal ion.
As the concentration of apotransferrin increases (with no Ru), cell growth initially
increases and then gradually decreases, so that at added concentrations greater than 50 tg/
mL, transferrin itself is toxic. When the effect of added apotransferrin was studied within the
range of approximately normal cell growth at [Ru] = 10 gM, growth inhibition increased as
the apotransferrin concentration increased. Since transferrin is known to bind ICR, such
behavior for this complex is not surprising. The observation of similar behavior for CCR,
suggests that CCR also enters cancer cells by a transferrin-mediated route and that this is
comparable in efficiency to that for ICR.
The similarity in transferrin effects may be due to the comparable aquation rates of the
two complexes. At 37’C CCR substitutes water for chloride at a rate of 3.5 x 10-5 s-1 (t 1/2
5.5 h),3 while that for ICR is 5.3 x 10-5 s-1 (t 1/2 = 3.7 h).28 Considering that cellular uptake
and transfer into the cell nucleus precedes DNA binding, these substitution rates seem slow
in accounting for the amount of ruthenium binding to the intracellular DNA. More rapid
substitution is consistent with an activation-by-reduction pathway.
Conclusion
Both cationic (CCR) and anionic (ICR) antitumor complexes behaved remarkably simi-
larly, suggesting analogous mechanisms of action, which probably involves transferrin binding
to actively transport the Ru into the cancer cell, possibly followed by intracellular activation
by reduction to facilitate DNA binding. On average for the various oxygen tensions and for
both complexes, IC50’s occur when one ruthenium is coordinated per 1000-2000 DNA base
pairs.
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